EFFECTS OF PEMBROLIZUMAB ON THE TUMOR MICROENVIRONMENT (TME) AFTER ONE PRESURGERY TREATMENT CYCLE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): PHASE 1B KEYNOTE-173 STUDY

被引：2

作者：

Schmid, Peter ^{[1
]}

Park, Yeon Hee ^{[2
]}

Munoz-Couselo, Eva ^{[3
]}

Kim, Sung-Bae ^{[4
]}

Sohn, Joohyuk ^{[5
]}

Im, Seock-Ah ^{[6
]}

Holgado, Esther ^{[7
]}

Foukakis, Theodoros ^{[8
,9
]}

Kuemmel, Sherko ^{[10
]}

Dent, Rebecca ^{[11
]}

Sun, Yuan ^{[12
]}

Huang, Lingkang ^{[12
]}

Yearley, Jennifer ^{[12
]}

Jelinic, Petar ^{[12
]}

Karantza, Vassiliki ^{[12
]}

Cortes, Javier ^{[3
]}

机构：

[1] Ctr Expt Canc Med, London, England

[2] Samsung Med Ctr, Seoul, South Korea

[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[5] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[6] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea

[7] Ramon y Cajal Univ, Madrid, Spain

[8] Karolinska Inst, Solna, Sweden

[9] Karolinska Univ Hosp, Theme Canc, Breast Canc Ctr, Solna, Sweden

[10] Kliniken Essen Mitte, Essen, Germany

[11] Int Breast Canc Ctr Quironsalud Grp, Singapore, Singapore

[12] Merck & Co Inc, Kenilworth, NJ USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.338

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

338

引用

页码：A364 / A364

页数：1

共 50 条

[21] Phase 1b/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.
Sohn, Joohyuk
Kim, Gun Min
Lee, Keun Seok
Kim, Sung-Bae
Kim, Jee Hung
Ahn, Hee Kyung
Lee, Jieun
Park, Kyong Hwa
Kim, Jee Hyun
Lee, Kyoung Eun
Shin, Eui-Cheol
Park, Su-Hyung
Yang, Se Hwan
Heo, MinKyu
Woo, Jung Won
Sung, Young Chul
Im, Young Hyuck
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[22] Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
Batalini, Felipe
Xiong, Niya
Tayob, Nabihah
Polak, Madeline
Eismann, Julia
Cantley, Lewis C.
Shapiro, Geoffrey, I
Adalsteinsson, Viktor
Winer, Eric P.
Konstantinopoulos, Panagiotis A.
D'Andrea, Alan
Swisher, Elizabeth M.
Matulonis, Ursula A.
Wulf, Gerburg M.
Mayer, Erica L.
CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1493 - 1499
[23] Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Tolaney, Sara M.
Kalinsky, Kevin
Kaklamani, Virginia G.
D'Adamo, David R.
Aktan, Gursel
Tsai, Michaela L.
O'Regan, Ruth M.
Kaufman, Peter A.
Wilks, Sharon T.
Andreopoulou, Eleni
Patt, Debra A.
Yuan, Yuan
Wang, Grace
Savulsky, Claudio
Xing, Dongyuan
Kleynerman, Ella
Karantza, Vassiliki
Diab, Sami
CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3061 - 3068
[24] A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC)
Isakoff, Steven J.
Tung, Nadine M.
Yin, Jun
Tayob, Nabihah
Parker, Joanne
Rosenberg, Julie
Bardia, Aditya
Spring, Laura
Park, Hannah
Collins, Maya
Barry, William T.
Severgnini, Mariano
Peterkin, Doris
Tolaney, Sara M.
CANCER RESEARCH, 2022, 82 (04)
[25] EFFICACY AND SAFETY OF GX-I7 PLUS PEMBROLIZUMAB FOR HEAVILY PRETREATED PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER: THE PHASE 1B/2 KEYNOTE-899 STUDY
Sohn, Joo
Im, Young Hyuk
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A197 - A198
[26] Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
Park, Y. H.
Im, S-A.
Ahn, J-H.
Kim, M. H.
Cortes, J.
Dent, R. A.
Pusztai, L.
McArthur, H. L.
Kummel, S.
Denkert, C.
O'Shaughnessy, J.
Mouret-Reynier, M-A.
Ferreira, M. I. R.
Cortes, M. Gion
Boileau, J-F.
Hui, R.
Zhu, Y.
Pan, W.
Karantza, V. V.
Schmid, P.
ANNALS OF ONCOLOGY, 2023, 34 : S1467 - S1468
[27] Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
Han, Hyo
Diab, Sami
Alemany, Carlos
Basho, Reva
Brown-Glaberman, Ursa
Meisel, Jane
Pluard, Timothy
Cortes, Javier
Dillon, Patrick
Ettl, Johannes
Kuemmel, Sherko
Sanchez, Luis Manso
Oliveira, Mafalda
O'Shaughnessy, Joyce
Papish, Steven
Sinha, Rajni
Sterrenberg, Danielle
Stringer-Reasor, Erica
Tsai, Michaela
Vazquez, Rafael Villanueva
Wuerstlein, Rachel
Wang, Yinghui
Wang, Zejing
Boni, Valentina
CANCER RESEARCH, 2020, 80 (04)
[28] Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Adams, S.
Loi, S.
Toppmeyer, D.
Cescon, D. W.
De Laurentiis, M.
Nanda, R.
Winer, E. P.
Mukai, H.
Tamura, K.
Armstrong, A.
Liu, M. C.
Iwata, H.
Ryvo, L.
Wimberger, P.
Rugo, H. S.
Tan, A. R.
Jia, L.
Ding, Y.
Karantza, V.
Schmid, P.
ANNALS OF ONCOLOGY, 2019, 30 (03) : 405 - 411
[29] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Dillon, Patrick
Basho, Reva
Han, Hyo S.
Kolberg, Hans-Christian
Tkaczuk, Katherine
Zahrah, George
Gion, Maria
Voss, Herman
Meisel, Jane
Pluard, Timothy
Fox, Jenny
Oliveira, Mafalda
Brown-Glaberman, Ursa
Stringer-Reasor, Erica
Manso, Luis
Kuemmel, Sherko
Chen, Lin Chi
Wu, Sheng
Croft, Brandon
Boni, Valentina
CANCER RESEARCH, 2023, 83 (05)
[30] Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)
Meisel, Jane Lowe
Pluard, Timothy J.
Vinayak, Shaveta
Stringer-Reasor, Erica Michelle
Brown-Glaberman, Ursa
Dillon, Patrick Michael
Basho, Reva K.
Varadarajan, Ramya
O'Shaughnessy, Joyce
Han, Hyo S.
Sinha, Rajni
Fox, Jenny R.
Villanueva, Rafael
Chen, Lin Chi
Wu, Sheng
Li, Hong
Tran, Sinhan
Manso, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →